Tacitus Therapeutics Launches in Collaboration with Mount Sinai to Develop Stem Cell Therapies for Life-Threatening Diseases
Tacitus Therapeutics exclusively licenses technology for expansion, differentiation and engineering of hematopoietic stem cells for use in therapeutic applications Tacitus Therapeutics, a clinical-stage company, has launched in collaboration with the Mount Sinai Health System to develop stem cell therapies initially targeting blood …
Nines Debuts Mission to Redefine Radiology, Delivering Next-level Patient Care
Nines’ unique approach to teleradiology reimagines radiology together with engineering and data science prowess to bring a new level of patient care Nines debuts as the first-of-its-kind teleradiology practice that combines top quality radiologists and world-class engineering to deliver high-quality diagnostics and …
Human Immune Monitoring Center at Mount Sinai to Analyze the Effectiveness of a Novel Cancer Therapy Drug
The Human Immune Monitoring Center (HIMC) at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo® (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology company Regeneron Pharmaceuticals, Inc and Sanofi. While …
Onegevity Health Acquires Global Licensing Rights to Mount Sinai’s Lab100
Clinic and research lab offers patients access to comprehensive health assessment, expands clinical understanding of disease prevention and provides wealth of health outcomes data Onegevity Health, LLC, a New York City-based health technology company focused on biometric data, artificial intelligence and personalized …
EKF Diagnostics Holding plc Announces Preferred Partner Arrangement with Mount Sinai
Opportunity to support digital health platform for Inflammatory Bowel Disease September 10, 2019 — EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has entered into a non-exclusive Preferred Partner Arrangement with Mount Sinai Innovation Partners (MSIP). MSIP is …
FDA Grants Breakthrough Device Designation to KidneyIntelX™
Provides Priority Regulatory Review of AI-Enabled Diagnostic for Fast-Progressing Kidney Disease NEW YORK, May 2, 2019 /PRNewswire/ – Renalytix AI plc (RENX.L), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that it has been granted Breakthrough Device designation by the U.S. Food …
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases
New York, NY (January 15, 2019) – The Icahn School of Medicine at Mount Sinai has entered into two exclusive licenses to develop the drug pentosan polysulfate sodium for the treatment of mucopolysaccharidosis (MPS), with Australia-based company Paradigm Biopharmaceuticals Ltd. (ASX: PAR) …
Sanofi, Sema4, Mount Sinai Collaborate on Largest Asthma Study of Its Kind
New York, NY (December 04, 2018) — Sema4, a patient-centered predictive health company, and the Mount Sinai Health System today announced the launch of a five-year collaborative study with Sanofi designed to provide new insights into the biological mechanisms and other factors …
RenalytixAI Raises $29 Million to Commercialize AI-Enabled Clinical Diagnostic Solutions for Kidney Disease
Mount Sinai Health System announced today that RenalytixAI PLC, a Mount Sinai exclusive licensee and development collaborator, had completed a public listing that valued the company at $85 million on the London Stock Exchange’s Alternative Investment Market. The public listing raised $29 …
Mount Sinai and AllerGenis, LLC Announce Partnership to Bring Novel, Precision Diagnostics to Food Allergy Patients
New Diagnostic Technology Will Provide Information to Both Patients and Clinicians More than 30 million people in the United States and Europe have food allergies, according to the National Institute of Allergy and Infectious Diseases, National Institutes of Health. AllerGenis’ food allergy …